Multiple Myeloma
GPRC5D-Targeted Therapy Continues to be Effective After Dose Reduction in R/R Multiple Myeloma
At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.
Read More
Advancing Myeloma Treatment With Blood-Based MRD Testing
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Listen
FDA Approves Adjuvant Alectinib in ALK+ NSCLC
The FDA approved adjuvant alectinib following tumor resection for the treatment of patients with ALK-positive non-small cell lung cancer.
Navigating the Landscape of Immunotherapy Toxicities
Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.
FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
Targeting Multiple Myeloma With the Latest Therapies
In an interview with Targeted Oncology, Adam D. Cohen, MD, discussed the impressive efficacy of FDA-approved agents, alongside their toxicity profiles, for the treatment of multiple myeloma.
